Kinneret Advisory LLC acquired a new stake in shares of Celgene Co. (NASDAQ:CELG) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 9,212 shares of the biopharmaceutical company’s stock, valued at approximately $590,000.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Bruderman Asset Management LLC bought a new stake in Celgene during the fourth quarter worth $25,000. Murphy Pohlad Asset Management LLC bought a new stake in Celgene during the fourth quarter worth $25,000. Athena Capital Advisors LLC bought a new stake in Celgene during the fourth quarter worth $27,000. Berman Capital Advisors LLC bought a new stake in Celgene during the fourth quarter worth $32,000. Finally, Doyle Wealth Management bought a new stake in Celgene during the fourth quarter worth $44,000. Hedge funds and other institutional investors own 74.19% of the company’s stock.
In related news, Director Ernest Mario acquired 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 12th. The shares were acquired at an average price of $89.99 per share, with a total value of $179,980.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director James J. Loughlin sold 23,466 shares of the firm’s stock in a transaction dated Thursday, February 7th. The shares were sold at an average price of $87.29, for a total value of $2,048,347.14. Following the completion of the sale, the director now directly owns 62,102 shares in the company, valued at approximately $5,420,883.58. The disclosure for this sale can be found here. Corporate insiders own 0.39% of the company’s stock.
A number of research analysts have issued reports on CELG shares. Cantor Fitzgerald restated a “buy” rating and issued a $100.00 price objective on shares of Celgene in a research note on Thursday, January 3rd. reaffirmed a “buy” rating on shares of Celgene in a research report on Monday, December 3rd. William Blair reaffirmed a “buy” rating on shares of Celgene in a research report on Thursday, February 28th. Morgan Stanley dropped their price target on Celgene from $93.00 to $88.00 and set an “equal weight” rating on the stock in a research report on Wednesday, December 19th. Finally, Canaccord Genuity cut Celgene from a “buy” rating to a “hold” rating in a research report on Thursday, January 3rd. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $100.94.
Shares of CELG opened at $88.29 on Friday. The stock has a market cap of $62.01 billion, a P/E ratio of 11.60, a P/E/G ratio of 0.39 and a beta of 1.69. The company has a debt-to-equity ratio of 3.21, a quick ratio of 2.12 and a current ratio of 2.23. Celgene Co. has a 52-week low of $58.59 and a 52-week high of $95.30.
Celgene (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, January 31st. The biopharmaceutical company reported $2.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.32 by $0.07. The business had revenue of $4.04 billion for the quarter, compared to analysts’ expectations of $3.98 billion. Celgene had a return on equity of 114.66% and a net margin of 26.48%. During the same quarter in the prior year, the firm posted $2.00 EPS. As a group, research analysts expect that Celgene Co. will post 10.01 EPS for the current year.
COPYRIGHT VIOLATION WARNING: “9,212 Shares in Celgene Co. (CELG) Acquired by Kinneret Advisory LLC” was reported by Zolmax and is the property of of Zolmax. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://zolmax.com/investing/9212-shares-in-celgene-co-celg-acquired-by-kinneret-advisory-llc/2965589.html.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Featured Story: How a Strangle Strategy is different from a Straddle Strategy
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.